Peripheral oxytocin and vasopressin: Biomarkers of psychiatric disorders? A comprehensive systematic review and preliminary meta-analysis

Psychiatry Research

Volumn 241, Issue , 2016, Pages 207-220

  Rutigliano, Grazia ^a,b   Rocchetti, Matteo ^a,c   Paloyelis, Yannis ^a   Gilleen, James ^a,e   Sardella, Alberto ^a   Cappucciati, Marco ^a,c   Palombini, Erika ^a,c   Dell'Osso, Liliana ^b   Caverzasi, Edgardo ^c   Politi, Pierluigi ^c   McGuire, Philip ^a   Fusar Poli, Paolo ^a,d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d South London and Maudlsey   (United Kingdom)

^e UNIVERSITY OF ROEHAMPTON   (United Kingdom)

Author keywords

Anorexia nervosa; Autism spectrum disorder; Bipolar disorder; Bulimia nervosa; Major depressive disorder; Obsessive compulsive disorder; Psychosis

Indexed keywords

BIOLOGICAL MARKER; OXYTOCIN; VASOPRESSIN; VASOPRESSIN DERIVATIVE;

ANOREXIA NERVOSA; AUTISM; BIPOLAR DISORDER; BODY FLUID; BULIMIA; EFFECT SIZE; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; MENTAL PATIENT; META ANALYSIS (TOPIC); OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN URINE LEVEL; PSYCHOSIS; REVIEW; SALIVA LEVEL; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW (TOPIC); META ANALYSIS; METABOLISM; REPRODUCIBILITY;

BIOMARKERS; HUMANS; MENTAL DISORDERS; OXYTOCIN; REPRODUCIBILITY OF RESULTS; VASOPRESSINS;

EID: 84966638761     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2016.04.117     Document Type: Review

References (139)

1. Alabdali A., Al-Ayadhi L., El-Ansary A. Association of social and cognitive impairment and biomarkers in autism spectrum disorders. J. Neuroinflamm. 2014, 11.
2. Al-Ayadhi L.Y. Altered oxytocin and vasopressin levels in autistic children in Central Saudi Arabia. Neurosciences 2005, 10(1):47-50.
3. Altemus M., Cizza G., Gold P.W. Chronic fluoxetine treatment reduces hypothalamic vasopressin secretion invitro. Brain Res. 1992, 593(2):311-313.
4. Altemus M., Fong J., Yang R., Damast S., Luine V., Ferguson D. Changes in cerebrospinal fluid neurochemistry during pregnancy. Biol. Psychiatry 2004, 56(6):386-392.
5. Altemus M., Pigott T., Kalogeras K.T., Demitrack M., Dubbert B., Murphy D.L., Gold P.W. Abnormalities in the regulation of vasopressin and corticotropin releasing-factor secretion in obsessive-compulsive disorder. Arch. Gen. Psychiatry 1992, 49(1):9-20.
6. Altemus M., Jacobson K.R., Debellis M., Kling M., Pigott T., Murphy D.L., Gold P.W. Normal CSF oxytocin and NPY levels in OCD. Biol. Psychiatry 1999, 45(7):931-933.
7. Anagnostou E., Soorya L., Brian J., Dupuis A., Mankad D., Smile S., Jacob S. Intranasal oxytocin in the treatment of autism spectrum disorders: a review of literature and early safety and efficacy data in youth. Brain Res. 2014, 1580:188-198.
8. Anagnostou E., Soorya L., Chaplin W., Bartz J., Halpern D., Wasserman S., Wang A.T., Pepa L., Tanel N., Kushki A., Hollander E. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol. Autism 2012, 3(1):16.
9. Andari E., Duhamel J.-R., Zalla T., Herbrecht E., Leboyer M., Sirigu A. Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc. Natl. Acad. Sci. USA 2010, 107(9):4389-4394.
10. Appelgren B. Reflex and hormonal influences on cerebral control of water-balance - studies of alimentary and cardiovascular factors, and of systematic angiotensin in the regulation of water-intake and adh secretion. Acta Physiol. Scand. 1982, 1-39.
11. Baumgartner T., Heinrichs M., Vonlanthen A., Fischbacher U., Fehr E. Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. Neuron 2008, 58(4):639-650.
12. Beckmann H., Lang R.E., Gattaz W.F. Vasopressin oxytocin in cerebrospinal-fluid of schizophrenic-patients and normal controls. Psychoneuroendocrinology 1985, 10(2):187-191.
13. Bendz H., Aurell M. Drug-induced diabetes insipidus: incidence, prevention and management. Drug Saf. 1999, 21(6):449-456.
14. Bendz H., Sjodin I., Aurell M. Renal function on and off lithium in patients treated with lithium for 15 years or more. A controlled, prospective lithium-withdrawal study. Nephrol. Dial. Transplant. 1996, 11(3):457-460.
15. Bertsch K., Schmidinger I., Neumann I.D., Herpertz S.C. Reduced plasma oxytocin levels in female patients with borderline personality disorder. Horm. Behav. 2013, 63(3):424-429.
16. Blevins J.E., Ho J.M. Role of oxytocin signaling in the regulation of body weight. Rev. Endocr. Metab. Disord. 2013, 14(4):311-329.
17. Boso M., Emanuele E., Politi P., Pace A., Arra M., di Nemi S.U., Barale F. Reduced plasma apelin levels in patients with autistic spectrum disorder. Arch. Med. Res. 2007, 38(1):70-74.
18. Carmichael M.S., Humbert R., Dixen J., Palmisano G., Greenleaf W., Davidson J.M. Plasma oxytocin increases in the human sexual response. J. Clin. Endocrinol. Metab. 1987, 64(1):27-31.
19. Carroll B.J., Feinberg M., Greden J.F., Tarika J., Albala A.A., Haskett R.F., James N.M., Kronfol Z., Lohr N., Steiner M., de Vigne J.P., Young E. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch. Gen. Psychiatry 1981, 38(1):15-22.
20. Cervantes P., Gelber S., Kin F.N., Nair V.N., Schwartz G. Circadian secretion of cortisol in bipolar disorder. J. Psychiatry Neurosci. 2001, 26(5):411-416.
21. Chang S.W., Platt M.L. Oxytocin and social cognition in rhesus macaques: implications for understanding and treating human psychopathology. Brain Res. 2014, 1580:57-68.
22. Christensen J.C., Shiyanov P.A., Estepp J.R., Schlager J.J. Lack of association between human plasma oxytocin and interpersonal trust in a prisoner's dilemma paradigm. PLoS One 2014, 9(12):e116172.
23. Cooper H., Hedges L., Valentine J. Handbook of Research Synthesis and Meta-Analysis 2009, Russell Sage Foundation., New York, NY, USA.
24. Crowley W.R. Neuroendocrine regulation of lactation and milk production. Compr. Physiol. 2015, 5(1):255-291.
25. Cui S.S., Bowen R.C., Gu G.B., Hannesson D.K., Yu P.H., Zhang X. Prevention of cannabinoid withdrawal syndrome by lithium: involvement of oxytocinergic neuronal activation. J. Neurosci. 2001, 21(24):9867-9876.
26. Daban C., Vieta E., Mackin P., Young A.H. Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatr. Clin. N. Am. 2005, 28(2):469-480.
27. Demitrack M.A., Lesem M.D., Listwak S.J., Brandt H.A., Jimerson D.C., Gold P.W. CSF oxytocin in anorexia-nervosa and bulimia-nervosa - clinical and pathophysiologic considerations. Am. J. Psychiatry 1990, 147(7):882-886.
28. Dinan T.G. Glucocorticoids and the genesis of depressive illness. A psychobiological model. Br. J. Psychiatry 1994, 164(3):365-371.
29. Domes G., Heinrichs M., Michel A., Berger C., Herpertz S.C. Oxytocin improves "mind-reading" in humans. Biol. Psychiatry 2007, 61(6):731-733.
30. Duval S., Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000, 56(2):455-463.
31. Elman I., Lukas S., Shoaf S.E., Rott D., Adler C., Breier A. Effects of acute metabolic stress on the peripheral vasopressinergic system in schizophrenia. J. Psychopharmacol. 2003, 17(3):317-323.
32. Emsley R., Potgieter A., Taljaard F., Joubert G., Gledhill R. Water-excretion and plasma vasopressin in psychotic disorders. Am. J. Psychiatry 1989, 146(2):250-253.
33. Evans S., Shergill S.S., Averbeck B.B. Oxytocin decreases aversion to angry faces in an associative learning task. Neuropsychopharmacology 2010, 35(13):2502-2509.
34. Evrard F., da Cunha M.P., Lambert M., Devuyst O. Impaired osmoregulation in anorexia nervosa: a case-control study. Nephrol. Dial. Transplant. 2004, 19(12):3034-3039.
35. Feifel D., Macdonald K., Nguyen A., Cobb P., Warlan H., Galangue B., Minassian A., Becker O., Cooper J., Perry W., Lefebvre M., Gonzales J., Hadley A. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol. Psychiatry 2010, 68(7):678-680.
36. Feldman R., Golan O., Hirschler-Guttenberg Y., Ostfeld-Etzion S., Zagoory-Sharon O. Parent child interaction and oxytocin production in pre-schoolers with autism spectrum disorder. Br. J. Psychiatry 2014, 205(2):107-112.
37. Frank G.K., Kaye W.H., Altemus M., Greeno C.G. CSF oxytocin and vasopressin levels after recovery from bulimia nervosa and anorexia nervosa, bulimic subtype. Biol. Psychiatry 2000, 48(4):315-318.
38. Fujisawa T.X., Tanaka S., Saito D.N., Kosaka H., Tomoda A. Visual attention for social information and salivary oxytocin levels in preschool children with autism spectrum disorders: an eye-tracking study. Front. Neurosci. 2014, 8. 295-295.
39. Gimpl G., Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol. Rev. 2001, 81(2):629-683.
40. Glovinsky D., Kalogeras K.T., Kirch D.G., Suddath R., Wyatt R.J. Cerebrospinal-fluid oxytocin concentration in schizophrenic-patients does not differ from control subjects and is not changed by neuroleptic medication. Schizophr. Res. 1994, 11(3):273-276.
41. Goekoop J.G., de Winter R.P.F., de Rijk R., Zwinderman K.H., Frankhuijzen-Sierevogel A., Wiegant V.M. Depression with above-normal plasma vasopressin: validation by relations with family history of depression and mixed anxiety and retardation. Psychiatry Res. 2006, 141(2):201-211.
42. Gold P.W., Kaye W., Robertson G.L., Ebert M. Abnormalities in plasma and cerebrospinal-fluid arginine vasopressin in patients with anorexia-nervosa. N. Engl. J. Med. 1983, 308(19):1117-1123.
43. Goldman M., Marlow-O'Connor M., Torres I., Carter C.S. Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophr. Res. 2008, 98(1-3):247-255.
44. Goldman M.B. The mechanism of life-threatening water imbalance in schizophrenia and its relationship to the underlying psychiatric illness. Brain Res. Rev. 2009, 61(2):210-220.
45. Goldstein G., Fava M., Culler M., Fisher A., Rickels K., Lydiard R.B., Rosenbaum J. Elevated plasma thymopoietin associated with therapeutic nonresponsiveness in major depression. Biol. Psychiatry 2000, 48(1):65-69.
46. Griebel G., Beeske S., Stahl S.M. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies. J. Clin. Psychiatry 2012, 73(11):1403-1411.
47. Grinevich V., Knobloch-Bollmann H.S., Eliava M., Busnelli M., Chini B. Assembling the puzzle: pathways of oxytocin signaling in the brain. Biol. Psychiatry 2015.
48. Guastella A.J., Kenyon A.R., Alvares G.A., Carson D.S., Hickie I.B. Intranasal arginine vasopressin enhances the encoding of happy and angry faces in humans. Biol. Psychiatry 2010, 67(12):1220-1222.
49. Guastella A.J., Einfeld S.L., Gray K.M., Rinehart N.J., Tonge B.J., Lambert T.J., Hickie I.B. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol. Psychiatry 2010, 67(7):692-694.
50. Gumley A., Braehler C., Macbeth A. A meta-analysis and theoretical critique of oxytocin and psychosis: prospects for attachment and compassion in promoting recovery. Br. J. Clin. Psychol. 2014, 53(1):42-61.
51. Hashimoto H., Uezono Y., Ueta Y. Pathophysiological function of oxytocin secreted by neuropeptides: a mini review. Pathophysiology: Off. J. Int. Soc. Pathophysiol./ISP 2012, 19(4):283-298.
52. Heinrichs M., von Dawans B., Domes G. Oxytocin, vasopressin, and human social behavior. Front. Neuroendocrinol. 2009, 30(4):548-557.
53. Heinrichs M., Baumgartner T., Kirschbaum C., Ehlert U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol. Psychiatry 2003, 54(12):1389-1398.
54. Heuser I., Bissette G., Dettling M., Schweiger U., Gotthardt U., Schmider J., Lammers C.H., Nemeroff C.B., Holsboer F. Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment. Depression Anxiety 1998, 8(2):71-79.
55. Hillerer K.M., Jacobs V.R., Fischer T., Aigner L. The maternal brain: an organ with peripartal plasticity. Neural Plast. 2014, 2014:574159.
56. Hoffman E.R., Brownley K.A., Hamer R.M., Bulik C.M. Plasma, salivary, and urinary oxytocin in anorexia nervosa: a pilot study. Eat. Behav. 2012, 13(3):256-259.
57. Hoge E.A., Pollack M.H., Kaufman R.E., Zak P.J., Simon N.M. Oxytocin levels in social anxiety disorder. CNS Neurosci. Ther. 2008, 14(3):165-170.
58. Hoge E.A., Lawson E.A., Metcalf C.A., Keshaviah A., Zak P.J., Pollack M.H., Simon N.M. Plasma oxytocin immunoreactive products and response to trust in patients with social anxiety disorder. Depression Anxiety 2012, 29(11):924-930.
59. Hollander E., Novotny S., Hanratty M., Yaffe R., DeCaria C.M., Aronowitz B.R., Mosovich S. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology 2003, 28(1):193-198.
60. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000, 23(5):477-501.
61. Husslein P. [The importance of oxytocin and prostaglandins to the mechanism of labor in humans]. Wien. Klin. Wochenschr. Suppl. 1984, 155:1-32.
62. Inder W.J., Donald R.A., Prickett T.C.R., Frampton C.M., Sullivan P.F., Mulder R.T., Joyce P.R. Arginine vasopressin is associated with hypercortisolemia and suicide attempts in depression. Biol. Psychiatry 1997, 42(8):744-747.
63. Higgins, J.P.T., Green, S., 2011. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 ed. The Cochrane Collaboration.
64. Jobst A., Dehning S., Ruf S., Notz T., Buchheim A., Henning-Fast K., Meissner D., Meyer S., Bondy B., Muller N., Zill P. Oxytocin and vasopressin levels are decreased in the plasma of male schizophrenia patients. Acta Neuropsychiatr. 2014, 26(6):347-355.
65. Jokinen J., Chatzittofis A., Hellstrom C., Nordstrom P., Uvnas-Moberg K., Asberg M. Low CSF oxytocin reflects high intent in suicide attempters. Psychoneuroendocrinology 2012, 37(4):482-490.
66. Kagerbauer S.M., Martin J., Schuster T., Blobner M., Kochs E.F., Landgraf R. Plasma oxytocin and vasopressin do not predict neuropeptide concentrations in human cerebrospinal fluid. J. Neuroendocrinol. 2013, 25(7):668-673.
67. Keri S., Kiss I., Kelemen O. Sharing secrets: oxytocin and trust in schizophrenia. Soc. Neurosci. 2009, 4(4):287-293.
68. Knafo A., Israel S., Darvasi A., Bachner-Melman R., Uzefovsky F., Cohen L., Feldman E., Lerer E., Laiba E., Raz Y., Nemanov L., Gritsenko I., Dina C., Agam G., Dean B., Bornstein G., Ebstein R.P. Individual differences in allocation of funds in the dictator game associated with length of the arginine vasopressin 1a receptor RS3 promoter region and correlation between RS3 length and hippocampal mRNA. Genes Brain Behav. 2008, 7(3):266-275.
69. Kudoh A., Kudo M., Ishihara H., Matsuki A. Increased plasma vasopressin and atrial natriuretic peptide in chronic schizophrenic patients during abdominal surgery. Neuropsychobiology 1998, 37(4):169-174.
70. Landgraf R., Neumann I.D. Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Front. Neuroendocrinol. 2004, 25(3-4):150-176.
71. Lawson E.A., Donoho D.A., Blum J.I., Meenaghan E.M., Misra M., Herzog D.B., Sluss P.M., Miller K.K., Klibanski A. Decreased nocturnal oxytocin levels in anorexia nervosa are associated with low bone mineral density and fat mass. J. Clin. Psychiatry 2011, 72(11):1546-1551.
72. Lawson E.A., Holsen L.M., Santin M., Meenaghan E., Eddy K.T., Becker A.E., Herzog D.B., Goldstein J.M., Klibanski A. Oxytocin secretion is associated with severity of disordered eating psychopathology and insular cortex hypoactivation in anorexia nervosa. J. Clin. Endocrinol. Metab. 2012, 97(10):E1898-E1908.
73. Leckman J.F., Goodman W.K., North W.G., Chappell P.B., Price L.H., Pauls D.L., Anderson G.M., Riddle M.A., McSwigganhardin M., McDougle C.J., Barr L.C., Cohen D.J. Elevated cerebrospinal-fluid levels of oxytocin in obsessive-compulsive disorder - comparison with tourettes-syndrome and healthy controls. Arch. Gen. Psychiatry 1994, 51(10):782-792.
74. Legros, J.J., Ansseau, M., Swaab, D.F., Saper, C.B., Kremer, H.P.H., Dewied, D., 1992. Neurohypophyseal peptides and psychopathology, in: Swaab, D.F., Hofman, M.A., Mirmiran, M., Ravid, R., Vanleeuwen, F.W. (Eds.), Human Hypothalamus in Health and Disease, pp. 455-461.
75. Leng G., Ludwig M. Intranasal oxytocin: myths and delusions. Biol. Psychiatry 2015.
76. Leng G., Pineda Reyes R., Sabatier N., Ludwig M. The posterior pituitary: from Geoffrey Harris to our present understanding. J. Endocrinol. 2015.
77. Lipsey M., Wilson D. Practical Meta-Analysis 2000, Sage Publications, Thousand Oaks, CA.
78. Ludwig M., Leng G. Dendritic peptide release and peptide-dependent behaviours. Nat. Rev. Neurosci. 2006, 7(2):126-136.
79. Ludwig M., Callahan M.F., Neumann I., Landgraf R., Morris M. Systemic osmotic stimulation increases vasopressin and oxytocin release within the supraoptic nucleus. J. Neuroendocr. 1994, 6(4):369-373.
80. Ludwig M., Sabatier N., Bull P.M., Landgraf R., Dayanithi G., Leng G. Intracellular calcium stores regulate activity-dependent neuropeptide release from dendrites. Nature 2002, 418(6893):85-89.
81. Borenstein, M.H.L., Higgins, J., Rothstein, H, 2005. Comprehensive Meta-Analysis Version 2. Biostat, Englewood, NJ, USA.
82. Macdonald K., Feifel D. Oxytocin in schizophrenia: a review of evidence for its therapeutic effects. Acta Neuropsychiatr. 2012, 24(3):130-146.
83. MacDonald K., MacDonald T.M. The peptide that binds: a systematic review of oxytocin and its prosocial effects in humans. Harv. Rev. Psychiatry 2010, 18(1):1-21.
84. Marazziti D., Catena Dell'osso M. The role of oxytocin in neuropsychiatric disorders. Curr. Med. Chem. 2008, 15(7):698-704.
85. Martin A., State M., Anderson G.M., Kaye W.M., Hanchett J.M., McConaha C.W., North W.G., Leckman J.F. Cerebrospinal fluid levels of oxytocin in Prader-Willi syndrome: a preliminary report. Biol. Psychiatry 1998, 44(12):1349-1352.
86. McCullough M.E., Churchland P.S., Mendez A.J. Problems with measuring peripheral oxytocin: can the data on oxytocin and human behavior be trusted?. Neurosci. Biobehav. Rev. 2013, 37(8):1485-1492.
87. Mens W.B., Witter A., van Wimersma Greidanus T.B. Penetration of neurohypophyseal hormones from plasma into cerebrospinal fluid (CSF): half-times of disappearance of these neuropeptides from CSF. Brain Res. 1983, 262(1):143-149.
88. Merali Z., Kent P., Du L., Hrdina P., Palkovits M., Faludi G., Poulter M.O., Bedard T., Anisman H. Corticotropin-releasing hormone, arginine vasopressin, gastrin-releasing peptide, and neuromedin B alterations in stress-relevant brain regions of suicides and control subjects. Biol. Psychiatry 2006, 59(7):594-602.
89. Meyer-Lindenberg A., Domes G., Kirsch P., Heinrichs M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat. Rev. Neurosci. 2011, 12(9):524-538.
90. Miller M., Bales K.L., Taylor S.L., Yoon J., Hostetler C.M., Carter C.S., Solomon M. Oxytocin and vasopressin in children and adolescents with autism spectrum disorders: sex differences and associations with symptoms. Autism Res. 2013, 6(2):91-102.
91. Modahl C., Green L., Fein D., Morris M., Waterhouse L., Feinstein C., Levin H. Plasma oxytocin levels in autistic children. Biol. Psychiatry 1998, 43(4):270-277.
92. Moos F., Poulain D.A., Rodriguez F., Guerne Y., Vincent J.D., Richard P. Release of oxytocin within the supraoptic nucleus during the milk ejection reflex in rats. Exp. Brain Res. 1989, 76(3):593-602.
93. Neumann I.D. Stimuli and consequences of dendritic release of oxytocin within the brain. Biochem. Soc. Trans. 2007, 35(Pt 5):1252-1257.
94. Nomura S., Ito T., Yamamoto E., Sumigama S., Iwase A., Okada M., Shibata K., Ando H., Ino K., Kikkawa F., Mizutani S. Gene regulation and physiological function of placental leucine aminopeptidase/oxytocinase during pregnancy. Biochim. Biophys. Acta 2005, 1751(1):19-25.
95. Ohsawa H., Kishimoto T., Shimayoshi N., Matsumura K., Tahara K., Kitera K., Higashiura N., Noriyama Y., Matsumoto H., Hirai M., Ikawa G. Atrial-natriuretic-peptide and arginine-vasopressin secretion in schizophrenic-patients. Acta Psychiatr. Scand. 1993, 88(2):130-134.
96. Ozsoy S., Esel E., Kula M. Serum oxytocin levels in patients with depression and the effects of gender and antidepressant treatment. Psychiatry Res. 2009, 169(3):249-252.
97. Padfield P.L., Park S.J., Morton J.J., Braidwood A.E. Plasma-levels of antidiuretic-hormone in patients receiving prolonged lithium-therapy. Br. J. Psychiatry 1977, 130:144-147.
98. Pagani J.H., Zhao M., Cui Z., Williams Avram S.K., Caruana D.A., Dudek S.M., Young W.S. Role of the vasopressin 1b receptor in rodent aggressive behavior and synaptic plasticity in hippocampal area CA2. Mol. Psychiatry 2014.
99. Pagel T., Baldessarini R.J., Franklin J., Baethge C. Characteristics of patients diagnosed with schizoaffective disorder compared with schizophrenia and bipolar disorder. Bipolar Disord. 2013, 15(3):229-239.
100. Paulson J.F., Bazemore S.D. Prenatal and postpartum depression in fathers and its association with maternal depression: a meta-analysis. JAMA 2010, 303(19):1961-1969.
101. Pedersen C.A., Gibson C.M., Rau S.W., Salimi K., Smedley K.L., Casey R.L., Leserman J., Jarskog L.F., Penn D.L. Intranasal oxytocin reduces psychotic symptoms and improves theory of mind and social perception in schizophrenia. Schizophr. Res. 2011, 132(1):50-53.
102. Pitts A.F., Samuelson S.D., Meller W.H., Bissette G., Nemeroff C.B., Kathol R.G. Cerebrospinal-fluid corticotropin-releasing hormone, vasopressin, and oxytocin concentrations in treated patients with major depression and controls. Biol. Psychiatry 1995, 38(5):330-335.
103. Raskind M.A., Courtney N., Murburg M.M., Backus F.I., Bokan J.A., Ries R.K., Dorsa D.M., Weitzman R.E. Antipsychotic-drugs and plasma vasopressin in normals and acute schizophrenic-patients. Biol. Psychiatry 1987, 22(4):453-462.
104. Rilling J.K., Demarco A.C., Hackett P.D., Chen X., Gautam P., Stair S., Haroon E., Thompson R., Ditzen B., Patel R., Pagnoni G. Sex differences in the neural and behavioral response to intranasal oxytocin and vasopressin during human social interaction. Psychoneuroendocrinology 2014, 39:237-248.
105. Robertson G.L. Antidiuretic hormone. Normal and disordered function. Endocrinol. Metab. Clin. N. Am. 2001, 30(3):671-694. (vii).
106. Rocchetti M., Radua J., Paloyelis Y., Xenaki L.A., Frascarelli M., Caverzasi E., Politi P., Fusar-Poli P. Neurofunctional maps of the 'maternal brain' and the effects of oxytocin: a multimodal voxel-based meta-analysis. Psychiatry Clin. Neurosci. 2014, 68(10):733-751.
107. Rubin L.H., Carter C.S., Drogos L., Pournajafi-Nazarloo H., Sweeney J.A., Maki P.M. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr. Res. 2010, 124(1-3):13-21.
108. Rubin L.H., Carter C.S., Bishop J.R., Pournajafi-Nazarloo H., Harris M.S.H., Hill S.K., Reilly J.L., Sweeney J.A. Peripheral vasopressin but not oxytocin relates to severity of acute psychosis in women with acutely-ill untreated first-episode psychosis. Schizophr. Res. 2013, 146(1-3):138-143.
109. Rubin L.H., Carter C.S., Bishop J.R., Pournajafi-Nazarloo H., Drogos L.L., Hill S.K., Ruocco A.C., Keedy S.K., Reilly J.L., Keshavan M.S., Pearlson G.D., Tamminga C.A., Gershon E.S., Sweeney J.A. Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders. Schizophr. Bull. 2014, 40(6):1374-1384.
110. Rubin R.T., O'Toole S.M., Rhodes M.E., Sekula L.K., Czambel R.K. Hypothalamo-pituitary-adrenal cortical responses to low-dose physostigmine and arginine vasopressin administration: sex differences between major depressives and matched control subjects. Psychiatry Res. 1999, 89(1):1-20.
111. Ryan M.C.M., Sharifi N., Condren R., Thakore J.H. Evidence of basal pituitary-ad renal overactivity in first episode, drug naive patients with schizophrenia. Psychoneuroendocrinology 2004, 29(8):1065-1070.
112. Sarai M., Matsunaga H. ADH secretion in schizophrenic-patients on antipsychotic-drugs. Biol. Psychiatry 1989, 26(6):576-580.
113. Sasayama D., Hattori K., Teraishi T., Hori H., Ota M., Yoshida S., Arima K., Higuchi T., Amano N., Kunugi H. Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia. Schizophr. Res. 2012, 139(1-3):201-206.
114. Silva S.M., Madeira M.D., Ruela C., Paula-Barbosa M.M. Prolonged alcohol intake leads to irreversible loss of vasopressin and oxytocin neurons in the paraventricular nucleus of the hypothalamus. Brain Res. 2002, 925(1):76-88.
115. Song Z., McCann K.E., McNeill J.Kt, Larkin T.E., Huhman K.L., Albers H.E. Oxytocin induces social communication by activating arginine-vasopressin V1a receptors and not oxytocin receptors. Psychoneuroendocrinology 2014, 50:14-19.
116. Sorensen P.S., Gjerris A., Hammer M. Cerebrospinal-fluid vasopressin in neurological and psychiatric-disorders. J. Neurol. Neurosurg. Psychiatry 1985, 48(1):50-57.
117. Spruce B.A., Baylis P.H., Burd J., Watson M.J. Variation in osmoregulation of arginine vasopressin during the human menstrual-cycle. Clin. Endocrinol. 1985, 22(1):37-42.
118. Stoop R. Neuromodulation by oxytocin and vasopressin. Neuron 2012, 76(1):142-159.
119. Strauss G.P., Keller W.R., Koenig J.I., Gold J.M., Frost K.H., Buchanan R.W. Plasma oxytocin levels predict social cue recognition in individuals with schizophrenia. Schizophr. Res. 2015, 162(1-3):47-51.
120. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., Moher D., Becker B.J., Sipe T.A., Thacker S.B. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of observational studies in epidemiology (MOOSE) group. JAMA 2000, 283(15):2008-2012.
121. Szeto A., McCabe P.M., Nation D.A., Tabak B.A., Rossetti M.A., McCullough M.E., Schneiderman N., Mendez A.J. Evaluation of enzyme immunoassay and radioimmunoassay methods for the measurement of plasma oxytocin. Psychosom. Med. 2011, 73(5):393-400.
122. Taurines R., Schwenck C., Lyttwin B., Schecklmann M., Jans T., Reefschlager L., Geissler J., Gerlach M., Romanos M. Oxytocin plasma concentrations in children and adolescents with autism spectrum disorder: correlation with autistic symptomatology. Atten. Deficit Hyperact. Disord. 2014, 6(3):231-239.
123. Thompson R., Gupta S., Miller K., Mills S., Orr S. The effects of vasopressin on human facial responses related to social communication. Psychoneuroendocrinology 2004, 29(1):35-48.
124. Thompson R.R., George K., Walton J.C., Orr S.P., Benson J. Sex-specific influences of vasopressin on human social communication. Proc. Natl. Acad. Sci. USA 2006, 103(20):7889-7894.
125. Turan T., Uysal C., Asdemir A., Kilic E. May oxytocin be a trait marker for bipolar disorder?. Psychoneuroendocrinology 2013, 38(12):2890-2896.
126. Uvanas-Moberg K., Arn I., Magnusson D. The psychobiology of emotion: the role of the oxytocinergic system. Int. J. Behav. Med. 2005, 12(2):59-65.
127. Uzunova G., Pallanti S., Hollander E. Excitatory/inhibitory imbalance in autism spectrum disorders: Implications for interventions and therapeutics. World J. Biol. Psychiatry 2015, 1-13.
128. van Londen L., Kerkhof G.A., van den Berg F., Goekoop J.G., Zwinderman K.H., Frankhuijzen-Sierevogel A.C., Wiegant V.M., de Wied D. Plasma arginine vasopressin and motor activity in major depression. Biol. Psychiatry 1998, 43(3):196-204.
129. Veenema A.H., Neumann I.D. Central vasopressin and oxytocin release: regulation of complex social behaviours. Prog. Brain Res. 2008, 170:261-276.
130. Walsh P., Spelman L., Sharifi N., Thakore J.H. Mate patients with paranoid schizophrenia have greater ACTH and cortisol secretion in response to metoclopramide-induced AVP release. Psychoneuroendocrinology 2005, 30(5):431-437.
131. Walss-Bass C., Fernandes J.M., Roberts D.L., Service H., Velligan D. Differential correlations between plasma oxytocin and social cognitive capacity and bias in schizophrenia. Schizophr. Res. 2013, 147(2-3):387-392.
132. Walum H., Westberg L., Henningsson S., Neiderhiser J.M., Reiss D., Igl W., Ganiban J.M., Spotts E.L., Pedersen N.L., Eriksson E., Lichtenstein P. Genetic variation in the vasopressin receptor 1a gene (AVPR1A) associates with pair-bonding behavior in humans. Proc. Natl. Acad. Sci. USA 2008, 105(37):14153-14156.
133. Wathes D.C., Swann R.W. Is oxytocin an ovarian hormone?. Nature 1982, 297(5863):225-227.
134. Watson S., Gallagher P., Smith M.S., Young A.H., Ferrier I.N. Lithium, arginine vasopressin and the dex/CRH test in mood disordered patients. Psychoneuroendocrinology 2007, 32(5):464-469.
135. Wersinger S.R., Ginns E.I., O'Carroll A.M., Lolait S.J., Young W.S. Vasopressin V1b receptor knockout reduces aggressive behavior in male mice. Mol. Psychiatry 2002, 7(9):975-984.
136. Wotjak C.T., Ganster J., Kohl G., Holsboer F., Landgraf R., Engelmann M. Dissociated central and peripheral release of vasopressin, but not oxytocin, in response to repeated swim stress: new insights into the secretory capacities of peptidergic neurons. Neuroscience 1998, 85(4):1209-1222.
137. You Z.D., Li J.H., Song C.Y., Lu C.L., He C. Oxytocin mediates the inhibitory action of acute lithium on the morphine dependence in rats. Neurosci. Res. 2001, 41(2):143-150.
138. Yuen K.W., Garner J.P., Carson D.S., Keller J., Lembke A., Hyde S.A., Kenna H.A., Tennakoon L., Schatzberg A.F., Parker K.J. Plasma oxytocin concentrations are lower in depressed vs. healthy control women and are independent of cortisol. J. Psychiatr. Res. 2014, 51:30-36.
139. Zak P.J., Kurzban R., Matzner W.T. Oxytocin is associated with human trustworthiness. Horm. Behav. 2005, 48(5):522-527.